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Background/Aims: Although crizotinib is standard chemotherapy for advanced 
anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), 
clinical factors affecting progression-free survival (PFS) have not been reported. 
The purpose of this study was to identify clinical factors affecting PFS of crizo-
tinib and develop a prognostic model for advanced ALK-positive NSCLC.
Methods: Clinicopathologic features of patients enrolled in PROFILE 1001, 1005, 
1007, and 1014 (training cohort) were reviewed. We conducted multivariate Cox 
analysis for PFS and overall survival (OS) in the training cohort (n = 159) and gen-
erated a proportional hazards model based on significant clinicopathologic fac-
tors, and then validated the model in an independent validation cohort (n = 40).
Results: In the training cohort, the objective response rate was 81.5%. Median 
PFS and OS from the start of crizotinib were 12.4 and 31.3 months, respectively. 
Multivariate Cox analysis showed poor performance status, number of metastatic 
organs (≥ 3), and no response to crizotinib independently associated shorter PFS. 
Based on a score derived from these three factors, median PFS and OS of patients 
with one or two factors were significantly shorter compared to those without 
these factors (median PFS, 22.4 months vs. 10.5 months vs. 6.5 months; median 
OS, not reached vs. 29.1 months vs. 11.8 months, respectively; p < 0.001 for each 
group). This model also had validated in an independent validation cohort. 
Conclusions: Performance status, number of metastatic organs, and response to 
crizotinib affected PFS of crizotinib in ALK-positive NSCLC. Based on these fac-
tors, we developed a simple and useful prediction model for PFS.
Keywords: Crizotinib; Anaplastic lymphoma kinase; Lung neoplasms; Dis-
ease-free survival; Proportional hazards models
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INTRODUCTION
Anaplastic lymphoma kinase (ALK) is well validated ty-
rosine kinase target in non-small cell lung cancer (NS-
CLC) [1]. Echinoderm microtubule associated protein 
like 4 (EML4)-ALK fusion was first identified in NSCLC 
[2] and is found in approximately 3% to 5% of cases of 
NSCLC, defining a distinct molecular subtype of NS-
CLC [3-5]. Crizotinib is a multi-targeted small-molecule 
ALK inhibitor approved for the treatment of advanced 
ALK-positive NSCLC [1]. Randomized phase III trials 
have clearly shown that crizotinib significantly im-
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proves progression-free survival (PFS) when compared 
with conventional cytotoxic chemotherapy for previ-
ously treated or treatment-naïve advanced ALK-positive 
NSCLC (PROFILE 1007 and PROFILE 1014) [6,7]. Crizo-
tinib is currently the standard chemotherapy for 
ALK-positive NSCLC.
Even though the response rate of ALK-positive NS-
CLC to crizotinib is much higher than conventional cy-
totoxic chemotherapy, all patients who initially respond 
to crizotinib eventually develop acquired resistance and 
disease progression. Because of acquired resistance, cli-
nicians have difficulty in predicting when tumor pro-
gression will occur during crizotinib therapy in indi-
vidual patients. In this regard, it is clinically important 
to be able to predict the timing of disease progression 
during crizotinib treatment.
However, to date, clinicopathologic factors that sig-
nificantly affect PFS of crizotinib have not been report-
ed. Besides the delicate molecular work to understand 
primary and secondary resistance to crizotinib [8,9], 
pragmatic models to predict tumor progression with 
crizotinib might help the clinician to better determine 
the prognosis of patients before or during crizotinib 
treatment. The objectives of this study were to: (1) iden-
tify clinical factors affecting PFS of crizotinib and (2) 
develop a practical model for predicting disease pro-
gression in ALK-positive NSCLC with crizotinib.
METHODS
Study population
Medical records of patients diagnosed with ALK-posi-
tive NSCLC and receiving crizotinib were analyzed. We 
developed two independent cohorts (Supplementary 
Fig. 1). A training cohort consisted of patients who were 
enrolled in PROFILE 1001 (NCT00585195, n = 50) [1], 
PROFILE 1005 (NCT00932451, n = 78) [10], PROFILE 
1007 (NCT00932893, n = 12) [6], and PROFILE 1014 
(NCT01154140, n = 31) [7] clinical trials. An independent 
validation cohort included patients given compassion-
ate use crizotinib (n = 3) or treated with crizotinib after 
Korean Food and Drug Administration approval (n = 
37). ALK positivity in the training cohort was defined by 
ALK break-apart fluorescence in situ hybridization 
(FISH) assay, as described for each clinical trial [1,6,7,11]. 
Experienced pathologists (Y.K.J. and D.H.C.) from the 
Seoul National University Hospital confirmed NSCLC 
as ALK-positive when 15% or more of tumour cells 
showed split and/or isolated 3′ signals in 50 analyzed 
cells [12] using a Vysis ALK Break Apart FISH Probe Kit 
(Abbott Molecular Inc., Des Plaines, IL, USA) for pa-
tients in the validation cohort. Age, sex, smoking histo-
ry, initial performance status by Eastern Cooperative 
Oncology Group (ECOG), metastatic organs (such as 
brain, lung-to-lung, bone, liver, lymph node, and pleu-


















 No. mPFS (95% CI)  HR (95% CI) p value
Training cohort  159    12.4 (10.2–15.6) 1 


















 No. mOS (95% CI)   HR (95% CI) p value
Training cohort  159  31.3 (26.2–42.3)         1 
Validation cohort   40    NR (17.3–NR) 1.01 (0.52–1.96)   0.987
36 48 60
Figure 1. Progression-free survival and overall survival after crizotinib treatment. Kaplan-Meier curves for progression-free 
survival (A) and overall survival (B) according to training cohort (n = 159) and validation cohort (n = 40) are shown. mPFS, medi-
an progression-free survival; CI, confidence interval; HR, hazard ratio; mOS, median overall survival; NR, not reached. 
A B
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Treatment and response evaluation of crizotinib
After baseline imaging with computed tomography of 
the chest and abdomen and magnetic resonance imag-
ing of the brain (if previously known brain metastases 
or suspected by neurologic symptoms), patients re-
ceived oral crizotinib at a dose of 250 mg twice daily. 
Follow-up tumour assessment was performed every 6 
to 12 weeks during treatment until progression. Tu-
mour assessment was based on Response Evaluation 
Criteria In Solid Tumours (RECIST) 1.0 [14] for patients 
enrolled in PROFILE 1001 and by RECIST 1.1 [15] for 
others. PFS was calculated from the start date of crizo-
tinib treatment to the date of disease progression by 
RECIST criteria, as confirmed by imaging, death, or the 
last follow-up date if censored. Overall survival (OS) was 
measured from the initiation of crizotinib treatment 
until death or the last follow-up date, if censored.
Statistical analysis
Univariate and multivariate Cox proportional hazard 
regression analyses were performed, summarizing the 
hazard ratio (HR) and 95% confidence interval (CI) for 
each group. Survival analyses were carried out accord-
ing to the Kaplan-Meier method with the log-rank test 
to assess differences between the groups. All reported p 
values are two-sided and considered significant if p < 
0.05. All statistical analyses were carried out using STA-
TA version 12 (StataCorp LP, College Station, TX, USA).
Ethics
The study protocol was approved by the Institutional 
Review Board of Seoul National University Hospital 
(approval number: H-1411-098-628) and was conducted 
in accordance with the Principles of the Declaration of 
Helsinki. Informed consent was waived by the IRB, 
since it was retrospective analysis and did not affect the 
clinical outcome of the subject.  
RESULTS
Patient characteristics by treatment type and re-
sponse
Baseline clinicopathologic characteristics of the train-
ing and validation cohorts are summarised in Table 1. 
In the training cohort, the median age of patients given 
crizotinib was 54 years, and 91 (57.2%) were female. The 
majority of patients (79.9%) were initially diagnosed 
with stage IIIB/IV metastatic lung cancer, and the mean 
number of metastatic organs prior to crizotinib treat-
ment was 2.77 (range, 1 to 6). Twenty-six patients (16.4%) 
were given crizotinib as first-line treatment. Among the 
157 evaluable patients, the objective response rate (com-
plete and partial responses) was 81.5% (95% CI, 75.4% to 
87.6%). During a median follow-up of 45.5 months 
(range, 3.9 to 74.5), 136 patients (85.5%) experienced pro-
gression with crizotinib; 81 (50.9%) had died at the time 
of final analysis (January 11, 2015). Median PFS of crizo-
tinib was 12.4 months (95% CI, 10.2 to 15.6), and OS 
from the start of crizotinib was 31.3 months (95% CI, 
26.2 to 42.3). 
Patient characteristics were not different between the 
training and validation cohorts, except more patients in 
the validation cohort had poorer performance status (p 
= 0.022) and were more likely to receive crizotinib as 
their first-line treatment (p = 0.021). Median follow-up 
duration in the validation cohort was 14.7 months, 
which was significantly shorter than the training cohort 
(p < 0.001). Kaplan-Meier analyses of PFS and OS for 
training and validation cohorts are shown in Fig. 1.
We examined the hazard function for progression. 
Supplementary Fig. 2 shows kernel estimates of the 
hazard functions for progression in the training cohort. 
Crizotinib-treated ALK-positive NSCLC patients had a 
pattern of consistent progression without a peak risk of 
progression during 24 months. This finding suggested 
that disease progression can develop evenly during 
crizotinib.
Univariate and multivariate Cox proportional hazard 
regression analyses of PFS and OS
Univariate and multivariate Cox regression analyses of 
PFS and OS in the training cohort were performed (Ta-
ble 2). Univariate Cox regression analysis showed poor 
performance status (ECOG status 2 or 3), ≥ 3 metastatic 
organs, baseline brain metastasis, and no response to 
crizotinib (stable or progressive disease) significantly af-
fected shorter PFS and OS. In multivariate Cox regres-
sion analysis, three factors except baseline brain metas-
tasis were independently correlated with PFS and OS.
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Age, yr, median (range) 55 (14–88) 54 (25–79) 56 (14–87) 0.323
Sex
Male 80 (40.2) 68 (42.8) 12 (30)
Female 119 (59.8) 91 (57.2) 28 (70) 0.141
ECOG
0 34 (17.1) 29 (18.2) 5 (12.5)
1 145 (72.9) 114 (71.7) 31 (77.5)
2 18 (9.0) 16 (10.1) 2 (5)
3 2 (1.0) 0 2 (5) 0.022
Smoking
Never smoker 147 (73.9) 115 (72.3) 32 (80)
Current or ex-smoker 52 (26.1) 44 (27.7) 8 (20) 0.323
Pathology
Adenocarcinoma 196 (98.5) 156 (98.1) 40 (100)
Large cell carcinoma 2 (1.0) 2 (1.3) 0
Poorly-differentiated carcinoma 1 (0.5) 1 (0.6) 0 0.682
Palliative reason
Initial stage IIIB-IV 160 (80.4) 127 (79.9) 33 (82.5)
Recurred after surgery 39 (19.6) 32 (20.1) 7 (17.5) 0.708
No. of metastatic organs, mean ± SE 2.75 ± 0.09 2.77 ± 0.10 2.70 ± 0.19 0.763
Metastatic organ
CNS 81 (40.7) 73 (45.9) 8 (20) 0.003
Lung-to-lung 120 (60.3) 95 (59.8) 25 (62.5) 0.751
Bone 77 (38.7) 63 (39.6) 14 (35) 0.592
Liver 47 (23.6) 34 (21.4) 13 (32.5) 0.139
Lymph node 108 (54.3) 87 (54.7) 21 (52.5) 0.801
Pleura 78 (39.2) 61 (38.4) 17 (42.5) 0.632
Crizotinib line
First line 39 (19.6) 26 (16.4) 13 (32.5)
≥ Second line 160 (80.4) 133 (83.6) 27 (67.5) 0.021
Crizotinib response
CR 5 (2.5) 4 (2.5) 1 (2.5)
PR 155 (77.9) 124 (78) 31 (77.5)
SD 27 (13.6) 25 (15.7) 2 (5)
PD 7 (3.5) 4 (2.5) 3 (7.5)
Not evaluable 5 (2.5) 2 (1.3) 3 (7.5) 0.042
ORR 160 (82.5) 128 (81.5) 32 (86.5) 0.475
PFS, mon, median (95% CI) 12.4 (10.2–15.6) 12.4 (10.2–15.6) 15.6 (7.1–16.8) 0.439
OSa, mon, median (95% CI) 31.3 (26.7–42.3) 31.3 (26.2–42.3) NR (17.3–NR) 0.987
Follow-up, mon, median (range) 38.3 (2.1–74.5) 43.5 (3.9–74.5) 14.7 (2.1–54) < 0.001
Values are presented as number (%) unless otherwise indicated.
ECOG, Eastern Cooperative Oncology Group; SE, standard error of mean; CNS, central nervous system; CR, complete re-
sponse; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; PFS, progression-free 
survival; CI, confidential interval; OS, overall survival; NR, not reached.
aOverall survival from the initiation of crizotinib to death or last follow-up.
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A predicting model to predict PFS and OS
In multivariate Cox regression analysis, three indepen-
dent prognostic factors (ECOG performance status, 
number of metastatic organs, and crizotinib response) 
showed similar HR (range, 1.81 to 2.64). Hence, we de-
veloped a simple and practical model to predict survival 
by allocating 1 point for each factor. For example, a pa-
tient with an ECOG status (= 3), stable disease, and four 
metastatic organs had 3 points. We excluded the pa-
tients who could not evaluate crizotinib response due 
to early follow-up loss in this model. Based on points 
derived from significant clinical factors of ECOG status 
2 to 3, number of metastatic organs ≥ 3, and no response 
to crizotinib, patients were divided into three groups: 
those with 0 point, 1 point, and 2 to 3 points (n = 59, n = 
73, and n = 25, respectively). Median PFS of patients with 
0 point was 22.4 months (95% CI, 16.6 to 29), which was 
significantly prolonged compared to those with 1 point 
(median PFS 10.5 months; 95% CI, 9 to 12.6; p < 0.001), 
and 2 to 3 points (median PFS 6.5 months; 95% CI, 4 to 
10.2; p < 0.001) (Fig. 2A). Moreover, median OS of pa-
tients with 0 point was not reached and was also sig-
nificantly prolonged compared with those patients with 
1 point (median OS 29.1 months; 95% CI, 22.7 to 38.9; p < 
0.001), and 2 to 3 points (median OS 11.8 months; 95% 
CI, 4.6 to 20.6; p < 0.001) (Fig. 2B).
This model also fitted and retained statistical signifi-
cance in an independent validation cohort, even though 
number of patients included in the validation cohort 
was relatively small (n = 40). Based on the same criteria 
derived from the Cox regression model analyzed in the 
training cohort, patients in the validation cohort were 
also divided into three groups: those with 0 point, 1 
point, and 2 to 3 points (n = 15, n = 19, and n = 3, respec-
tively). Median PFS of patients in the validation cohort 
with 0 point was 25.9 months (95% CI, 16.5 to not 
reached), which was significantly prolonged compared 
with those patients with 1 point (median PFS 7.1 
months; 95% CI, 4.3 to 15.6; p < 0.001), and 2 to 3 points 
(median PFS 0.3 months; 95% CI, 0.3 to not reached; p < 
0.001) (Fig. 3A). Moreover, median OS of patients in the 
validation cohort with 0 point was not reached, which 
was also significantly longer than those patients with 1 
point (median OS 17.3 months; 95% CI, 7.9 months to 
not reached; p = 0.043) and 2 to 3 points (median OS not 
reached; 95% CI, 0.9 months to not reached; p = 0.019) 
(Fig. 3B). 
DISCUSSION
In our current study, we found that three clinicopatho-
logic factors (poor performance status [ECOG 2 to 3], ≥ 3 
metastatic organs, and no response to crizotinib) were 
significantly associated with shorter PFS and OS. As 

















 No. mPFS (95% CI)    HR (95% CI) p value 
0 point 59  22.4 (16.6–29)       1 
1 point 73  10.5 (9–12.6) 2.38 (1.60–3.54)  < 0.001
2–3 point  25    6.5 (4–10.2) 4.26 (2.50–7.26)  < 0.001
 No.   mOS (95% CI)     HR (95% CI) p value
0 point 59      NR (40.9–NR)        1 
1 point 73    29.1 (22.7–38.9)   2.37 (1.36–4.11)     0.002



















Figure 2. Survival analysis according to a proportional hazards model in training cohort. Kaplan-Meier curves for progres-
sion-free survival (A) and overall survival (B) after crizotinib treatment in the training cohort according to a proportional haz-
ards model are shown. Score indicates how many factors were present (i.e., Eastern Cooperative Oncology Group performance 
status, same or more than 2; number of metastatic organs, same or more than 3 organs; and no response by crizotinib treat-
ment). mPFS, median progression-free survival; CI, confidence interval; HR, hazard ratio; mOS, median overall survival.
A B
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crizotinib treatment, clinicians have difficulty in pre-
dicting when disease progression will occur in individ-
ual patients. Hence, predicting disease progression af-
ter crizotinib treatment is a clinically important issue. 
In this study, a simple and practical model to predict 
PFS of crizotinib was developed and validated in an in-
dependent cohort.
Clinicopathologic factors significantly associated with 
PFS and OS were similar to previously published re-
sults and showed that ECOG performance status and 
tumour burden were correlated with survival of epider-
mal growth factor receptor tyrosine kinase inhibitor 
(EGFR TKI) [13,16-20]. Although ECOG performance 
status is a common prognostic factor for cancer, to the 
Table 2. Univariate and multivariate Cox regression analyses of progression-free survival with crizotinib and overall survival 
in training cohort (n = 159)
Variable
Progression-free survival Overall survivala
Univariate Multivariate Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age 0.99 (0.98–1.01) 0.486 - - 1.01 (0.99–1.03) 0.113 - -
Sex
Female 1 - - 1 - -
Male 1.25 (0.89–1.76) 0.199 1.26 (0.81–1.94) 0.309
ECOG PS
0–1 1 1 1 1 0.002
≥ 2 2.29 (1.34–3.89) 0.002 1.80 (1.04–3.11) 0.035 3.69 (1.96–6.93) < 0.001 2.84 (1.48–5.48)
Smoking
Never 1 - - 1 - -
Current or  
ex-smoker
0.99 (0.68–1.45) 0.971 1.05 (0.65–1.69) 0.850
Palliative reason
Recurred 1 - - 1 - -
Metastatic 1.44 (0.94–2.23) 0.098 1.05 (0.61–1.82) 0.861
No. of metastatic organs
1–2 1 1 1 1
≥ 3 2.47 (1.73–3.53) < 0.001 2.58 (1.73–3.85) < 0.001 2.63 (1.64–4.20) < 0.001 3.05 (1.80–5.17) < 0.001
Baseline brain metastasis
No 1 1 1 1
Yes 1.76 (1.25–2.47) < 0.001 1.06 (0.72–1.54) 0.773 2.04 (1.31–3.19) 0.002 1.16 (0.72–1.87) 0.546
Crizotinib line
First-line 1 - - 1 - -




1 1 1 1
No response  
(SD + PD)
1.75 (1.14–2.68) 0.011 1.82 (1.16–2.85) 0.009 2.17 (1.28–3.70) 0.004 2.53 (1.43–4.47) 0.001
HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; CR, complete 
response; PR, partial response; SD, stable disease; PD, progressive disease.
aOverall survival from the initiation of crizotinib to death or last follow-up.
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best of our knowledge, its use in crizotinib-treated 
ALK-positive NSCLC has not been reported. As definite 
oncogenic addiction of ALK-positive NSCLC was shown 
in preclinical and clinical studies, one might expect 
that crizotinib treatment would be effective regardless 
of ECOG performance status. Moreover, the so called 
“Lazarus response” after EGFR TKI has been observed 
in treatment-naïve, poor performance status NSCLC pa-
tients with EGFR mutations [21]. Surely, molecular tar-
geted agents can be used in poor performance status 
patients without significant toxicity and with an expect-
ed high response rate. However, PFS of poor perfor-
mance status patients was shorter than that of good per-
formance status patients regardless of a high response 
rate. In our current study, performance status signifi-
cantly affected PFS of crizotinib in ALK-positive NSCLC.
A large number of metastatic organs was also an in-
dependent factor associated with an unfavorable prog-
nosis in ALK-positive NSCLC, which is in agreement 
with a previous study regarding EGFR TKI [16]. Al-
though there is no standard method to reflect overall 
tumor burden, a large number of metastatic organs can 
suggest a large tumor burden in individual patients. 
Cancer cells undergo selective pressure from chemo-
therapy and undergo a genotypical clonal evolution. In 
an animal model, a large tumor burden would be more 
likely to result in genetically complex tumors that 
would exhibit either primary or secondary resistance to 
erlotinib [22]. As resistant mutant clones might increase 
in proportion to tumor burden, the probability of de-
veloping resistant clones would be higher in a patient 
with a large tumor burden, and it is likely that these pa-
tients show shorter PFS of crizotinib. A prediction 
model consisting of ECOG performance status, number 
of metastatic organs, and response to crizotinib might 
guide physicians in estimating the prognosis of the in-
dividual patient as well as the timing of progression 
with crizotinib early during treatment. Interestingly, 
the proportional hazards model developed using mul-
tivariate Cox regression analysis of PFS also fitted OS in 
our current study. Extended survival in a good progno-
sis group might allow for use of other ALK inhibitors 
currently under development.
Median PFS in PROFILE 1014, which used crizotinib 
as a first-line treatment, was 10.9 months in the crizo-
tinib arm, but for PROFILE 1007, which included previ-
ously treated patients, was 7.7 months [6,7]. Results of 
PFS from previous trials would imply that crizotinib 
treatment as a first-line treatment would be the same 
or better than second-line treatments. In the current 
analysis, PFS of first-line crizotinib was not statistically 
longer than that of ≥ second line crizotinib (HR, 1.28; 
95% CI, 0.79 to 2.08; p = 0.321). To show OS benefits by 
first-line treatment compared to second or more than 
second-line treatment is not easy. However, the im-
provement in the quality of life in patients given crizo-
tinib in PROFILE 1014 [7], there is no reason to post-



































 No. mPFS (95% CI)    HR (95% CI) p value
0 point 15  25.9 (16.5–NR)     1 
1 point 19    7.1 (4.3–15.6)   32 (3.9–NR)  < 0.001
2–3 point    3    0.3 (0.3–NR) 112 (8.6–NR)  < 0.001  No.   mOS (95% CI)    HR (95% CI) p value
0 point 15       NR (17.5–NR)        1 
1 point 19    17.3 (7.9–NR)     9.1 (1.1–77)  0.043
2–3 point    3      NR (0.9–NR)     36 (1.8–NR)  0.019
Figure 3. Survival analysis according to a proportional hazards model in validation cohort. Kaplan-Meier curves for progres-
sion-free survival (A) and overall survival (B) after crizotinib treatment in the validation cohort according to a proportional 
hazards model are shown. Score indicates how many factors are present (i.e., Eastern Cooperative Oncology Group perfor-
mance status same or more than 2; number of metastases, same or more than 3 organs; and no response by crizotinib treat-
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second line treatment. As ECOG performance and 
number of metastatic organ are important, it seems to 
be better not to postpone crizotinib treatment. Al-
though baseline brain metastasis was significantly asso-
ciated with poor PFS and OS in univariate Cox analysis, 
but it was not much as significant in multivariate anal-
ysis. Since number of metastatic organ would include 
baseline brain metastasis, assessing overall tumor bur-
den would be more important compared to consider-
ing brain metastasis only when we predict PFS or OS of 
crizotinib.
Our study has some limitations. First, the true defini-
tion of disease progression can be vague, because of 
some patients have received crizotinib even after evi-
dence of progression according to RECIST criteria 
[14,15]. Disease progression after TKI does not always 
mean a development of acquired resistance or true 
treatment failure [23]. There are several evidences sup-
porting that continuing TKI beyond progression would 
benefit in EGFR-mutant NSCLC [24,25] and in ALK-pos-
itive NSCLC [26,27]. However, it has not been clearly 
shown in well-designed prospective studies regarding 
crizotinib treatment beyond progression. To minimize 
this bias, we defined progression and calculated PFS 
according to RECIST criteria which have been most 
commonly used. Second, OS differences using a pro-
portional hazards model could be affected by con-
founding factors, such as exposure to other second 
generation ALK inhibitors. Third, although our model 
was validated using an independent data set, the num-
ber of patients included in the validation cohort was 
relatively small. Therefore, it would be necessary to 
conduct an external validation of our model using an-
other independent patient population. Despite these 
limitations, the current study is the first to develop a 
practical model to predict PFS of crizotinib in ALK-pos-
itive NSCLC. In conclusion, we found that three inde-
pendent clinical factors—ECOG performance status, 
number of metastatic organs, and response to crizo-
tinib affect PFS of crizotinib in advanced ALK-positive 
NSCLC. Based on these factors, we also developed sim-
ple and useful prediction model for PFS, which could 
help define patient groups based on prognosis. Further 
studies are needed for external validation of this pre-
diction model.
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211 NSCLC/Crizotinib treatment
       50 PROFILE 1001
       78 PROFILE 1005
       12 PROFILE 1007
       31 PROFILE 1014
    3 Compassionate use
37 Prescribed after FDA approval
199 ALK FISH+/Crizotinib treatment
159 Training cohort: PROFILE 1001, 1005, 1007, 1014
   40 Validation cohort: compassionate use, prescribed
12 Confirmed ROS1+ in 
PROFILE 1001
Supplementary Figure 1. Consolidated Standards of Re-
porting Trials (CONSORT) diagram. NSCLC, non-small 
cell lung cancer; FDA, Food and Drug Administration; ALK, 
anaplastic lymphoma kinase; FISH, fluorescence in situ hy-
bridization.
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Numbers at risk 159 122 78 54 37 19 12 8 6
Progression events 0 35 42 23 14 12 6 2 1
6 12 18 24 30 36 42 48













Supplementary Figure 2. Smoothed hazard relapse rate as 
shown by hazard function of progression-free survival in 
the training cohort.
